Zacks Investment Research upgraded shares of RIGEL PHARMCTCL (RIGL) from NEUTRAL to OUTPERFORM on February 27, 2015, with a target price of $3.40.
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
To get a free copy of the research report on RIGEL PHARMCTCL (RIGL),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment